Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI, et al. Jukema JW, et al. Among authors: jansen h. Circulation. 1995 May 15;91(10):2528-40. doi: 10.1161/01.cir.91.10.2528. Circulation. 1995. PMID: 7743614 Clinical Trial.
The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JH, Bruschke AV, Henneman JA, Molhoek GP, Bruin T, Jansen H, Gagné E, Hayden MR, Kastelein JJ. Jukema JW, et al. Among authors: jansen h. Circulation. 1996 Oct 15;94(8):1913-8. doi: 10.1161/01.cir.94.8.1913. Circulation. 1996. PMID: 8873668 Clinical Trial.
Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group.
Groenemeijer BE, Hallman MD, Reymer PW, Gagné E, Kuivenhoven JA, Bruin T, Jansen H, Lie KI, Bruschke AV, Boerwinkle E, Hayden MR, Kastelein JJ. Groenemeijer BE, et al. Among authors: jansen h. Circulation. 1997 Jun 17;95(12):2628-35. doi: 10.1161/01.cir.95.12.2628. Circulation. 1997. PMID: 9193431 Clinical Trial.
-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group.
de Maat MP, Kastelein JJ, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, Bruschke AV, Kluft C. de Maat MP, et al. Among authors: jansen h. Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):265-71. doi: 10.1161/01.atv.18.2.265. Arterioscler Thromb Vasc Biol. 1998. PMID: 9484992 Review.
The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group.
Kastelein JJ, Groenemeyer BE, Hallman DM, Henderson H, Reymer PW, Gagné SE, Jansen H, Seidell JC, Kromhout D, Jukema JW, Bruschke AV, Boerwinkle E, Hayden MR. Kastelein JJ, et al. Among authors: jansen h. Clin Genet. 1998 Jan;53(1):27-33. doi: 10.1034/j.1399-0004.1998.531530106.x. Clin Genet. 1998. PMID: 9550358
High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants.
van Acker BA, Botma GJ, Zwinderman AH, Kuivenhoven JA, Dallinga-Thie GM, Sijbrands EJ, Boer JM, Seidell JC, Jukema JW, Kastelein JJ, Jansen H, Verhoeven AJ; REGRESS Study Group. van Acker BA, et al. Among authors: jansen h. Atherosclerosis. 2008 Sep;200(1):161-7. doi: 10.1016/j.atherosclerosis.2007.11.019. Epub 2007 Dec 27. Atherosclerosis. 2008. PMID: 18164013 Clinical Trial.
1,168 results